Machine learning operations platform Chief.AI, in partnership with the Medicines Discovery Catapult, has launched the first no-code, pay-as-you-go artificial intelligence (AI) platform for drug discovery.

The project is supported by a grant from Innovate UK, and will give small and medium-sized enterprises (SMEs) cloud-based access to AI models and data for drug discovery, diagnostics and clinical trials.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Chief.AI’s platform is the first no-code service of its type in the bioinformatics space, meaning SMEs can build applications quickly and without substantial internal IT capabilities.

The use of AI in drug discovery is growing rapidly, and is expected to transform the pharmaceutical industry more than any other emerging technology. Chief.AI’s platform allows SMEs to affordably access cutting-edge technology to minimise the hit-and-miss nature of drug discovery and identify novel therapies with enhanced speed and accuracy, the Manchester-based company said.

Given that around 90% of potential novel drug candidates fail, and that Chief.AI gives SMEs the option to pay only for the AI services they need, the platform could see drug discovery companies save not just time, but a significant amount of money.

Chief.AI founder Waqar Ali commented: “As an orchestrator of AI, we are delighted to be able to make access to AI easier and more effective for healthcare providers around the world.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Artificial intelligence will prove to be a great force multiplier for data intensive applications such as drug discovery and diagnostics, and with the help of the Medicines Discovery Catapult, Chief.AI is strategically poised to enable businesses around the world to connect to AI and reap these efficiencies seamlessly.”

The £370,000 funding for the Chief.AI project was awarded by Innovate UK in 2019.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact